The effects of dextromethorphan (DM), and its major metabolite dextrorphan (DX) on kainic acid-induced seizures in mice were examined. Intracerebroventricular DM or DX (5 or 10 μg/0.5μl) pretreatment significantly attenuated seizures induced by kainic acid (0.07 μg/0.07 μl) in a dose-related manner. DM or DX pretreatment significantly attenuated kainic acid-induced increases in AP-1 DNA-binding activity and fos-related antigen-immunoreactivity as well as neuronal loss in the hippocampus. DM appears to be a more potent neuroprotectant than DX. Since the high-affinity DM binding sites are recognized as being identical to the σ-1 site, we examined the role of the σ-1 receptor on the pharmacological action mediated by DM or DX. Pretreatment with the σ-1 receptor antagonist BD1047 (2.5 or 5 mg/kg, i.p.) blocked the neuroprotection by DM in a dose-related manner. This effect of BD 1047 was more pronounced in the animals treated with DM than in those treated with DX. Combined, our results suggest that metabolism of DM to DX is not essential for DM to exert its effect. They also suggest that DM provides neuroprotection from kainic acid via σ-1 receptor modulation.
|Number of pages
|Published - Jan 3 2003
Bibliographical noteFunding Information:
We thank Drs. J.S. Hong and M.J. Iadarola for donating antiserum against FRA. This study was supported by a grant of the Biomedical Brain Research Center Grant (01-PJ8-PG6-01NE01-0003), Ministry of Health and Welfare, Republic of Korea. Equipment at the Institute of Pharmaceutical Science (Kangwon National University) was used for this study.
- AP-1 DNA binding activity
- Fos-related antigen immunoreactivity
- σ-1 receptor
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology (all)
- Pharmacology, Toxicology and Pharmaceutics (all)